Quantitative high-throughput single-cell cytotoxicity assay for T cells.

Cancer immunotherapy can harness the specificity of immune response to target and eliminate tumors. Adoptive cell therapy (ACT) based on the adoptive transfer of T cells genetically modified to express a chimeric antigen receptor (CAR) has shown considerable promise in clinical trials(1-4). There are several advantages to using CAR(+) T cells for the treatment of cancers including the ability to target non-MHC restricted antigens and to functionalize the T cells for optimal survival, homing and persistence within the host; and finally to induce apoptosis of CAR(+) T cells in the event of host toxicity(5). Delineating the optimal functions of CAR(+) T cells associated with clinical benefit is essential for designing the next generation of clinical trials. Recent advances in live animal imaging like multiphoton microscopy have revolutionized the study of immune cell function in vivo(6,7). While these studies have advanced our understanding of T-cell functions in vivo, T-cell based ACT in clinical trials requires the need to link molecular and functional features of T-cell preparations pre-infusion with clinical efficacy post-infusion, by utilizing in vitro assays monitoring T-cell functions like, cytotoxicity and cytokine secretion. Standard flow-cytometry based assays have been developed that determine the overall functioning of populations of T cells at the single-cell level but these are not suitable for monitoring conjugate formation and lifetimes or the ability of the same cell to kill multiple targets(8). Microfabricated arrays designed in biocompatible polymers like polydimethylsiloxane (PDMS) are a particularly attractive method to spatially confine effectors and targets in small volumes(9). In combination with automated time-lapse fluorescence microscopy, thousands of effector-target interactions can be monitored simultaneously by imaging individual wells of a nanowell array. We present here a high-throughput methodology for monitoring T-cell mediated cytotoxicity at the single-cell level that can be broadly applied to studying the cytolytic functionality of T cells.

[1]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[2]  Steven A. Rosenberg,et al.  Adoptive immunotherapy for cancer: harnessing the T cell response , 2012, Nature Reviews Immunology.

[3]  C. Sumen,et al.  Intravital microscopy: visualizing immunity in context. , 2004, Immunity.

[4]  George Makedonas,et al.  Living in a house of cards: re‐evaluating CD8+ T‐cell immune correlates against HIV , 2011, Immunological reviews.

[5]  Hendrik Streeck,et al.  The role of IFN-γ Elispot assay in HIV vaccine research , 2009, Nature Protocols.

[6]  Navin Varadarajan,et al.  Rapid, efficient functional characterization and recovery of HIV-specific human CD8+ T cells using microengraving , 2012, Proceedings of the National Academy of Sciences.

[7]  J Christopher Love,et al.  A high-throughput single-cell analysis of human CD8⁺ T cell functions reveals discordance for cytokine secretion and cytolysis. , 2011, The Journal of clinical investigation.

[8]  W. Telford,et al.  Multiparametric analysis of apoptosis by flow and image cytometry. , 2004, Methods in molecular biology.

[9]  J. C. Love,et al.  Screening individual hybridomas by microengraving to discover monoclonal antibodies , 2009, Nature Protocols.

[10]  Hao Liu,et al.  CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. , 2011, The Journal of clinical investigation.

[11]  R. Koup,et al.  Intracellular cytokine optimization and standard operating procedure , 2006, Nature Protocols.

[12]  Martin Pule,et al.  Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. , 2011, Blood.

[13]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[14]  Ralph Weissleder,et al.  Intravital Imaging , 2011, Cell.